In 1997 an academic group at the University of Nottingham saw an opportunity to deliver sophisticated analytical and intellectual property consultancy services to the pharmaceutical industry and founded Molecular Profiles Ltd.

This early phase in our history has given our company a solid research foundation. This has led our team to go on to deliver advanced characterisation of pharmaceutical and biological materials and formulation services to many of the biggest pharmaceutical companies in the world.

Over the years, we have retained this science-led approach while broadening our service offering through the evolving needs of our clients. Dovetailing our early-stage drug development capabilities, we also have a dedicated clinical manufacturing facility that handles a range of non-sterile dosage forms including solids, liquids, semi-solids and inhaled products.

In September 2013, US-based Columbia Laboratories, now known as Juniper Pharmaceuticals acquired the Nottingham Molecular Profiles facility. Operating as a wholly-owned subsidiary, we now work closely with our parent company as its operational arm for the delivery of its successful product CRINONE® 8% (progesterone gel) as well as its contract services. Molecular Profiles is now Juniper Pharma Services.